Stifel Financial Corp. logo SF - Stifel Financial Corp.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 13
HOLD 9
SELL 0
STRONG
SELL
0
| PRICE TARGET: $93.44 DETAILS
HIGH: $99.33
LOW: $89.00
MEDIAN: $92.00
CONSENSUS: $93.44
UPSIDE: 28.72%

Stock News

KBW Announces 2026 Bank Honor Roll Award Winners

KBW Announces 2026 Bank Honor Roll Award Winners

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly-owned subsidiary of Stifel Financial Corp. (NYSE: SF), today named 17 U.S. banking institutions, just 6% of eligible banks, to the coveted 2026 KBW Bank Honor Roll. KBW congratulates the 10 returning members to this year's Honor Roll, including 1st Source Corporation (SRCE), BancFirst Corporation (BANF), Coastal Financial Corporation (CCB), Esquire Financial Holdings, Inc. (ESQ), First Citizens BancShares, Inc. (FCNCA), HomeTrust Bancshares, Inc. (HTB), Magyar Bancorp, Inc. (MGYR), Northeast Bank (NBN), NorthEast Community Bancorp, Inc. (NECB), and Pathward Financial, Inc. (CASH).

Apr 28, 2026 04:30 AM globenewswire.com
Stifel Financial: A High-Return, Diversified Franchise The Market Is Undervaluing

Stifel Financial: A High-Return, Diversified Franchise The Market Is Undervaluing

Stifel Financial is a durable, relationship-driven financial franchise compounding value across cycles, with a current price undervaluing its earnings power. Q1'26 results showed 15% YoY revenue growth, record wealth management, and firm-wide pretax margins above 22%, with broad-based segment contributions. SF's outlook is supported by strong investment banking pipelines, adviser recruitment, and AI-driven productivity, positioning it for cyclical upswing without requiring perfect conditions.

Apr 26, 2026 05:00 AM seekingalpha.com
Stifel Financial: IB Leads The Way Despite March Dealmaking Snag

Stifel Financial: IB Leads The Way Despite March Dealmaking Snag

Stifel Financial Corp. had decent results from pro-volatility businesses but even better results from businesses otherwise more threatened by the dealmaking slump. There may be some pause after Q1 in biotech depositories, but the decent market environment despite the Iran War may not threaten capital raising and industrial advisory too much. Growth should still be possible, though we wouldn't be surprised by some deceleration, even if overall dealmaking is supposed to have recovered, possibly driven by large tickets, though.

Apr 22, 2026 01:55 PM seekingalpha.com
Heartland Value Plus Fund Q1 2026 Portfolio Activity

Heartland Value Plus Fund Q1 2026 Portfolio Activity

The Value Plus Fund gained 4.95% in the first quarter, compared with the 4.96% gain for the Russell 2000 Value Index. For small-cap tech stocks, the first quarter proved to be quite strong, in part because this group had already suffered setbacks last year and, for the most part, valuations never got out of hand. One of the biggest detractors to our strategy's performance in the quarter was Stifel Financial.

Apr 15, 2026 10:30 PM seekingalpha.com
Stifel Welcomes Veteran Healthcare Bankers Ajay Pathak and Bill Reisner as Managing Directors in Public Finance

Stifel Welcomes Veteran Healthcare Bankers Ajay Pathak and Bill Reisner as Managing Directors in Public Finance

ST. LOUIS, March 12, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Ajay Pathak and Bill Reisner have joined the firm as Managing Directors in Stifel's Public Finance group to co-lead a differentiated healthcare practice. Both will be based in St. Louis, where they will accelerate the continued expansion of Stifel's public finance platform with a unique market offering that provides capital markets and advisory solutions for hospitals and health systems amid growing sector complexity.

Mar 12, 2026 05:00 AM globenewswire.com
Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum

Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum

WALTHAM, Mass.--(BUSINESS WIRE)--Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 3:00 pm ET. A live webcast of the company presentation will be available on the Company's website at www.korsana.com. A replay.

Mar 12, 2026 04:00 AM businesswire.com

Price Targets